GLP-1 Drug Shortage 2024: What You Need to Know

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The demand for GLP-1 receptor agonists has surged dramatically since 2023, creating real supply constraints for some branded formulations. However, the current landscape differs significantly from peak shortage periods—and compounded options through licensed 503A pharmacies continue to provide reliable access for patients seeking weight loss and metabolic support.

What Caused the GLP-1 Medication Shortage

The initial GLP-1 shortage emerged when branded semaglutide and tirzepatide prescriptions skyrocketed beyond manufacturing capacity. Early 2023 saw patients waiting months for Ozempic and Mounjaro refills. Multiple factors converged: FDA approval for weight loss, celebrity endorsements, television coverage, and growing clinical evidence fueled demand that manufacturers could not immediately match. Supply chain disruptions at Novo Nordisk and Eli Lilly facilities further delayed production.

By late 2024, branded supply has stabilized considerably. Manufacturers ramped up production across multiple facilities and expanded distribution networks. However, certain dosages, formulations, and regions still experience intermittent shortages. Insurance coverage remains inconsistent, and out-of-pocket costs for branded versions exceed $1,000 monthly for many patients, creating an affordability crisis even when medications are in stock.

Current GLP-1 Supply Status and Availability Trends

Today's GLP-1 landscape shows mixed signals. Branded semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) inventory has improved substantially from 2023 lows, though certain strengths remain subject to occasional backorders. Pharmacy chains report more consistent stock than early shortage periods, but patient access still hinges on insurance approval, prior authorization requirements, and regional pharmacy networks. Many patients face 2-4 week delays between prescription and dispensing.

Compounded semaglutide and tirzepatide from licensed 503A pharmacies have emerged as a stable alternative throughout supply fluctuations. These medications contain identical active ingredients to branded versions but bypass manufacturing bottlenecks since they are prepared in licensed compounding facilities. PlexusDx sources from multiple 503A compounding pharmacies, ensuring consistent availability regardless of branded supply conditions across all 50 states.

Why Compounded GLP-1 Offers Reliable Access

Compounded semaglutide and tirzepatide operate under different regulatory and manufacturing frameworks than branded medications. Licensed 503A compounding pharmacies prepare medications to individual prescription specifications, allowing them to scale production independently of large manufacturer constraints. This decentralized approach has proven resilient during supply disruptions. Compounded GLP-1 medications contain the same pharmaceutical-grade active ingredients as Ozempic and Mounjaro, but they cost significantly less and remain consistently available.

PlexusDx partners with licensed 503A compounding pharmacies to deliver semaglutide injections starting at just $149 per month, regardless of dose escalation—meaning patients never pay more as their dose increases. No insurance is required, no membership fees apply, and HSA and FSA accounts can be used for payment. This model eliminates the insurance approval bottleneck that delays many patients seeking branded options. Delivery arrives within 3-5 business days to all 50 states.

Comparing Branded vs. Compounded GLP-1 Medications

Branded semaglutide and tirzepatide undergo FDA approval processes that establish safety and manufacturing standards, offering certain regulatory assurances. However, compounded versions prepared by licensed 503A pharmacies must also meet strict quality, sterility, and potency standards under state pharmacy board oversight and federal regulations. Both options contain identical active pharmaceutical ingredients. The key difference lies in manufacturing location, regulatory pathway, and cost—not efficacy or safety profile when sourced from accredited 503A facilities.

Cost represents the most significant distinction between pathways. Branded semaglutide injections typically cost $900–$1,300 monthly out-of-pocket before insurance, while PlexusDx compounded semaglutide starts at $149 per month with no flat per-compound pricing increases. Insurance coverage varies widely for branded medications and often requires prior authorization delays. Compounded options eliminate insurance barriers entirely, making GLP-1 therapy financially accessible to patients who would otherwise postpone treatment due to cost or authorization timelines.

How to Access GLP-1 Therapy During Inventory Challenges

Patients seeking GLP-1 therapy should explore multiple pathways simultaneously if branded medications face local shortages. Working with a primary care provider or weight loss specialist remains essential to ensure medical appropriateness, rule out contraindications, and establish appropriate dosing. Once a prescription exists, patients can request their pharmacy check branded medication availability or explore compounded alternatives through platforms like PlexusDx that verify licensed 503A compounding sources. Many patients find compounded options preferable due to lower cost and faster fulfillment.

PlexusDx streamlines access by offering both semaglutide injections and oral formulations, tirzepatide injections and oral options, and the dual-compound GLP-Squared protocol. Patients can start therapy within days rather than weeks, with transparent pricing, no insurance gatekeeping, and optional genetic testing through the Precision Peptide Genetic Test ($99 add-on after first month) to identify individual peptide-pathway optimization. This personalized approach helps patients select the compound and delivery method most aligned with their physiology and lifestyle.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is there still a GLP-1 shortage in 2024?

Branded GLP-1 shortages have largely resolved, though certain dosages remain intermittently unavailable depending on region and insurance status. Compounded semaglutide and tirzepatide from licensed 503A pharmacies maintain consistent supply nationwide.

Are compounded GLP-1 medications as effective as branded versions?

Compounded semaglutide and tirzepatide contain identical active pharmaceutical ingredients to Ozempic, Wegovy, Mounjaro, and Zepbound. When prepared by licensed 503A compounding pharmacies meeting strict quality standards, efficacy and safety profiles mirror branded medications.

How much does PlexusDx compounded semaglutide cost compared to branded options?

PlexusDx semaglutide injections start at $149 per month, with pricing remaining flat regardless of dose increases—your dose may go up, but your price won't. Branded semaglutide typically costs $900–$1,300 monthly out-of-pocket. No insurance is required, and HSA/FSA accounts are accepted.

What if I'm allergic to semaglutide—can I try tirzepatide instead?

True IgE-mediated semaglutide allergy is rare but should be evaluated by an allergist before switching compounds. Tirzepatide (GLP-1/GIP receptor agonist) has a slightly different mechanism and side effect profile, making it suitable for some patients who experience intolerance to semaglutide.

What does the PlexusDx Precision Peptide Genetic Test reveal?

The Precision Peptide Genetic Test ($99 add-on after first month) analyzes 14 metabolic pathways and 150+ genetic insights related to peptide signaling, including variants in GLP1R, GIPR, FTO, and MC4R genes.

Is There a Shortage of GLP-1 Drugs? Understanding the Current Landscape